Drug Sponsors

Insmed names Will Lewis president and CEO

Tuesday, September 11, 2012 11:19 AM

Monmouth Junction, N.J.-based Insmed, a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from serious orphan lung diseases, has appointed Will Lewis president and CEO, effective immediately.

More... »

Annovation Biopharma raises $8M to develop novel anesthetics

Tuesday, September 11, 2012 08:00 AM

Annovation Biopharma, a biotech focused on safer therapies for anesthesia, has raised $8 million in a Series A financing led by Atlas Venture, Partners Innovation Fund (PIF) and new strategic investor The Medicines Company. 

More... »

ViroPharma expands in PA, creates 151 jobs

Tuesday, September 11, 2012 08:00 AM

ViroPharma, a biopharmaceutical company that focuses on rare diseases, will expand its operations in Exton, Penn., and create 151 new, high-paying jobs.

More... »

Abbott, Astellas collaborate on CMV vaccine trial

Monday, September 10, 2012 11:03 AM

Abbott has signed an agreement to collaborate with Astellas Pharma Global Development in a phase III clinical trial for ASP0113 (TransVax), an investigational vaccine licensed from Vical for preventing cytomegalovirus (CMV) reactivation in transplant patients.

More... »

MedImmune, WuXi AppTec form joint venture to develop novel biologic for Chinese market

Monday, September 10, 2012 10:31 AM

MedImmune, the global biologics arm of AstraZeneca, and WuXi AppTec, an R&D outsourcing company, have formed a joint venture to develop and commercialize MEDI5117, a novel biologic for autoimmune and inflammatory diseases, in China.

More... »

Galenea receives $3M to develop translational EEG biomarkers for schizophrenia

Friday, September 7, 2012 12:22 PM

Researchers at Galenea, based in Cambridge, Mass., and collaborator Dr. Kevin Spencer of the VA Boston Healthcare System and Harvard Medical School, have been awarded a five-year, $3 million grant from the National Institute of Mental Health (NIMH).

More... »

SFJ, Pfizer collaborate on phase III trial of dacomitinib in lung cancer

Friday, September 7, 2012 11:21 AM

The SFJ Pharmaceuticals Group (SFJ), a global drug development group of companies, has entered into a collaborative development agreement with Pfizer to conduct a phase III clinical trial of Pfizer's investigational pan-HER (pan-human epidermal growth factor receptor) inhibitor, dacomitinib (PF-00299804).

More... »

Spectrum completes acquisition of Allos

Friday, September 7, 2012 10:59 AM

Spectrum Pharmaceuticals (SPPI), an Irvine, Calif.-based biotech focused on hematology and oncology, has completed its acquisition of Allos Therapeutics, a Westminster, Colo.-based developer of small molecule drugs.

More... »

Jazz Pharmaceuticals to sell women's health business to Meda

Friday, September 7, 2012 10:31 AM

Jazz Pharmaceuticals, a specialty pharmaceutical company based in Dublin, has inked an agreement to sell its women's health business to Meda, an international specialty pharmaceutical company based in Sweden, for $95 million in cash.

More... »

F2G completes $30M financing round for anti-fungal compounds

Thursday, September 6, 2012 07:48 AM

F2G, an antifungal drug discovery and development company based in Manchester, U.K., has completed a $30 million equity financing round, which will be used to select a clinical candidate from the F3 series of advanced preclinical analogs and proceed to first in man studies.

More... »